SMStephen McDonald

Stephen McDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen McDonald has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Towards a minimal core dataset for systemic lupus erythematosus studies

    by Stephen McDonald, Jialin Teng, Chengde Yang, Michelle Barraclough, Graciela S Alarcon, Anca D Askanase, Sasha Bernatsky, Ann Elaine Clarke, Nathalie Costedoat-Chalumeau, Qiang Fu, et al.

    Objective: SLE is a complex, heterogenous autoimmune disease. SLE researchers do not always collect the same data, making comparative studies difficult. We aimed to ascertain what variables SLE clinical researchers commonly collect for SLE research. Our ultimate goal is to generate a minimal core dataset for future SLE studies. Methods: In 2020, we designed and distributed a questionnaire to members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) as well as additional active research centres in China. Our survey included 26 questions about the types of data that are routinely collected for research. Variables collected by ≥75% of participating respondents were used as a threshold for inclusion. Results: 18 of 36 invited respondents replied (8 from USA/Canada, 5 from China and 5 from Europe). Many key variables in the domains of sociodemographics, SLE specific, comorbidities, baseline haematology/biochemistry/immunology and treatment data were collected by ≥75% respondents including the 1997 American College of Rheumatology (ACR) Classification Criteria (83%), SLE Disease Activity Index-2000 (82%), current treatment (100%), drug name, dose, frequency and start date (75–100%) and complement C3/4 (94%). A range of other items was collected by 50–<75% of respondents including SLICC 2012 Criteria (67%), SLICC/ACR Damage Index (68%) and Short Form Health Survey-36 (53%). Less than 50% of respondents collect certain items including European Alliance of Associations for Rheumatology/ACR 2019 criteria (33%), British Isles Lupus Assessment Group scores (12%) and pneumococcal vaccine status (39%). Conclusions: The frequency with which an initial set of variables is collected in SLE cohorts globally was identified and can form the basis from which to develop a core minimum dataset for SLE. Further refinement and common definitions will be needed to finalise a minimal core dataset suitable for widespread use.

  • Open Access

    Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial

    by Stephen McDonald, Sean Yiu, Li Su, Caroline Gordon, Matt Truman, Laura Lisk, Neil Solomons, Ian N Bruce

    Objectives To identify predictors of overall lupus and lupus nephritis (LN) responses in patients with LN. Methods Data from the Aspreva Lupus Management Study (ALMS) trial cohort was used to identify baseline predictors of response at 6 months. Endpoints were major clinical response (MCR), improvement, complete renal response (CRR) and partial renal response (PRR). Univariate and multivariate logistic regressions with least absolute shrinkage and selection operator (LASSO) and cross-validation in randomly split samples were utilised. Predictors were ranked by the percentage of times selected by LASSO and prediction performance was assessed by the area under the receiver operating characteristics (AUROC) curve. Results We studied 370 patients in the ALMS induction trial. Improvement at 6 months was associated with older age (OR=1.03 (95% CI: 1.01 to 1.05) per year), normal haemoglobin (1.85 (1.16 to 2.95) vs low haemoglobin), active lupus (British Isles Lupus Assessment Group A or B) in haematological and mucocutaneous domains (0.61 (0.39 to 0.97) and 0.50 (0.31 to 0.81)), baseline damage (SDI>1 vs =0) (0.38 (0.16 to 0.91)) and 24-hour urine protein (0.63 (0.50 to 0.80)). LN duration 2–4 years (0.43 (0.19 to 0.97) vs Conclusions Baseline variables predicted 6-month outcomes in patients with SLE. While the modest performance of models emphasises the need for new biomarkers to advance this field, the factors identified can help identify those patients who may require novel treatment strategies.


  • Open Access

    Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate

    by Anne Barton, Meghna Jani, Christine Bundy, James Bluett, Stephen McDonald, Brian Keevil, Faraz Dastagir, Melissa Aris, Ian Bruce, Pauline Ho, et al.

    Objective: MTX remains the cornerstone for therapy for RA, yet research shows that non-adherence is significant and correlates with response to therapy. This study aimed to halve self-reported non-adherence to MTX at the Kellgren Centre for Rheumatology. Methods: An anonymous self-report adherence questionnaire was developed and data collected for 3 months prior to the introduction of interventions, and then regularly for the subsequent 2.5 years. A series of interventions were implemented, including motivational interviewing training, consistent information about MTX and development of a summary bookmark. Information on clinic times was collected for consultations with and without motivational interviewing. Surveys were conducted to ascertain consistency of messages about MTX. A biochemical assay was used to test MTX serum levels in patients at two time points: before and 2.8 years following introduction of the changes. Remission rates at 6 and 12 months post-MTX initiation were retrieved from patient notes and cost savings estimated by comparing actual numbers of new biologic starters compared with expected numbers based on the numbers of consultants employed at the two time points. Results: Between June and August 2016, self-reported non-adherence to MTX was 24.7%. Following introduction of the interventions, self-reported non-adherence rates reduced to an average of 7.4% between April 2018 and August 2019. Clinic times were not significantly increased when motivational interviewing was employed. Consistency of messages by staff across three key areas (benefits of MTX, alcohol guidance and importance of adherence) improved from 64% in September 2016 to 94% in January 2018. Biochemical non-adherence reduced from 56% (September 2016) to 17% (June 2019), whilst remission rates 6 months post-initiation of MTX improved from 13% in 2014/15 to 37% in 2017/18, resulting is estimated cost savings of £30 000 per year. Conclusion: Non-adherence to MTX can be improved using simple measures including focussing on the adherence and the benefits of treatment, and providing consistent information across departments.


  • Open Access

    AB0474 MORTALITY ACROSS RITUXIMAB-TREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP (BILAG) REGISTRY

    by Aysun Aksoy, Stephen McDonald, Eoghan Mccarthy, Ben Parker, Ian N. Bruce

    Background Mortality in Systemic Lupus Erythematosus (SLE) is elevated in comparison to the general population. Previously we have demonstrated improved disease control in response to Rituximab (RTX) therapy in a cohort of refractory SLE patients. Objectives To investigate mortality in refractory SLE patients treated with RTX and identify risk factors that may be associated with death. Methods All patients recruited to the BILAG-BR (both RTX treated and standard of care-SOC) were included from initial study visit to death or 3 years post last treatment change. Demographics, concurrent medication use, disease activity (BILAG/SLEDAI) and damage scores (SLICC-DI) were recorded. Information regarding mortality was collected from study centres and NHS digital national death registry. Baseline demographic data are presented using descriptive statistics performed using Stata (version 14). Results 830 patients were included (715 RTX-treated, 115 standard therapy). RTX-treated patients tended to have longer disease duration (10 vs 6.5 years respectively) and were more likely to have active musculoskeletal disease (% BILAG A or B: 39% vs 23%). Rates of renal (11% vs 16%) and neurological disease (12% vs 9%) were comparable between groups as were baseline SLICC-DI and SLEDAI scores. 33 deaths were reported. 28 (3.9%) RTX-treated patients (1.2 deaths/100 pt yrs follow up) and 5 (4.3%) non-RTX patients (1.5 deaths/100 pt yrs follow up). Cause of death was identifiable in 20 RTX treated patients. Infection was the commonest cause of death (10/20, 50%) followed by ischaemic heart disease (5/20, 25%) and malignancy (3/20, 15%). Median time to death for RTX-treated was 481 days. Risk factors associated with mortality within the RTX group included male gender, older age at diagnosis, renal disease, hypogammaglobulinaemia, high SLICC-DI and higher steroid use at last review (Table 1). Median cumulative RTX dosing was 2g for deceased and alive. Deceased RTX patients had a greater total number of co-morbidities at baseline (2.5 vs 0, p < 0.01) driven predominantly by the presence of hypertension (11/28, 39% vs 159/687, 25%, p = 0.05), ischaemic heart disease (4/28, 14% vs 11/687, 2%, p= 0.00) and diabetes (7/28, 25% vs 15/687, 2%, p = 0.00). Conclusion RTX treated patients do not appear to have higher mortality rates compared to patients starting SOC treatment. Mortality is associated with cardiovascular risk factors, higher steroid doses, hypogammaglobulinaemia and renal disease. Active management of these risk factors may lead to improved mortality outcomes. Deceased and alive RTX treated patients Disclosure of Interests Aysun Aksoy: None declared, Stephen McDonald: None declared, Eoghan McCarthy: None declared, Ben Parker Grant/research support from: GSK, Consultant for: AZ, UCB, GSK, Ian N. Bruce Grant/research support from: Genzyme Sanofi, GlaxoSmithKline, Consultant for: AstraZeneca, Eli Lilly, GlaxoSmithKline, ILTOO Pharma, MedImmune, Merck Serono, Speakers bureau: GlaxoSmithKline, UCB Pharma


  • Can serum interleukin-17 and interleukin-10 levels predict response to biologic treatments in patients with rheumatoid arthritis?

    by Stephen McDonald, Rachel Reed, Ivona Baricevic-Jones, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Stephanie Ling, Darren Plant, Anne Barton

    Rheumatology key message. IL-17 levels do not predict response/non-response to anti-TNF drugs.


  • Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis

    by C G Leonard, C Masih, S McDonald, G Taylor, N Maiden, P J Leyden

    Background: Chronic rhinosinusitis has many risk factors; however, the effect of anti-tumour necrosis factor therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes.Method: A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps criteria.Results: A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the anti-tumour necrosis factor therapy population was 20 per cent (95 per cent confidence interval = 12.84–27.16). When compared using a chi-square test, for a two-by-two contingency table, this finding was significant against the prevalence recorded in the normal population.Conclusion: This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-tumour necrosis factor therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies currently diagnosed and treated as chronic rhinosinusitis.


  • Does rheumatoid arthritis disease activity correlate with weather conditions?

    by E. M. Savage, D. McCormick, S. McDonald, O. Moore, M. Stevenson, A. P. Cairns

    To determine whether rheumatoid arthritis disease activity correlates with changing weather conditions. A longitudinal analysis of 133 patients attending the Department of Rheumatology, Musgrave Park Hospital, Belfast was performed. Participants had a diagnosis of rheumatoid arthritis and were receiving subcutaneous anti-TNF therapy (Adalimumab or Etanercept) for a period of >6 months. Data were collected at five time points. This included tender joint count, swollen joint count, patient visual analogue score (VAS), erythrocyte sedimentation rate, C-reactive protein, VAS, and DAS-28 (Disease Activity Score). Each weather factor (maximum, minimum temperature, pressure, rainfall, sunshine, humidity, and wind-speed) was analysed against each patients’ DAS-28 score at five time points, using an analysis of covariance. A significant correlation was noted between low DAS-28 and increased hours of sunshine (p < 0.001). Sunny conditions were associated with a DAS-28 reduction of 0.037 (95 % CI −0.059, −0.016) p < 0.001. A significant correlation between humidity and DAS-28 was also noted (p = 0.016). Increased humidity was associated with an increased DAS-28 of 0.007 (95 % CI 0.001, 0.013) p = 0.016. Higher temperatures were associated with a non-significant decrease in DAS-28 (p = 0.16). In this study, rheumatoid arthritis disease activity (as measured by DAS-28) was significantly lower in both more sunny and less humid conditions.